Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease
NCT ID: NCT05919511
Last Updated: 2025-08-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
1500 participants
OBSERVATIONAL
2023-08-01
2027-10-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Close Assessment and Testing for Chronic Graft Versus Host Disease, CATCH Study
NCT04188912
Chronic GVHD Response Measures Validation
NCT01902576
BMT Autologous MSCs for GvHD
NCT02359929
Improving Outcomes Assessment in Chronic GVHD
NCT00637689
Screening for Subjects to Participate in Studies of Blood Disorders
NCT00695123
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
At risk for GVHD
Equal or Greater than 18 years old post alloSCT
Non-Interventional
This is an observational study
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Non-Interventional
This is an observational study
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Allogeneic SCT 90 to 180 days prior to enrollment
* Able to comprehend and willing to provide informed consent
* Willing and able to complete participant-assessment questionnaires either alone or with minimal assistance from a caregiver and/or trained site personnel
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Incyte Corporation
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama Birmingham
Birmingham, Alabama, United States
Mayo Clinic Arizona
Phoenix, Arizona, United States
City of Hope
Duarte, California, United States
USC Norris Comprehensive Cancer Center
Los Angeles, California, United States
University of Colorado
Aurora, Colorado, United States
Mayo Clinic Jacksonville
Jacksonville, Florida, United States
AdventHealth Orlando
Orlando, Florida, United States
Moffit Cancer Center
Orlando, Florida, United States
Emory University
Atlanta, Georgia, United States
Georgia Cancer Center
Augusta, Georgia, United States
Northwestern University
Chicago, Illinois, United States
Rush University Medical Group
Chicago, Illinois, United States
The University of Chicago
Chicago, Illinois, United States
Loyola University Medical Center
Maywood, Illinois, United States
The University of Kansas Clinical Research Center
Fairway, Kansas, United States
Tulane Cancer Center
New Orleans, Louisiana, United States
University of Maryland Medical Center
Baltimore, Maryland, United States
Massachusetts Cancer Research Center
Boston, Massachusetts, United States
Corewell Health
Grand Rapids, Michigan, United States
Mayo Clinic Rochester
Rochester, Minnesota, United States
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
Levine Cancer Institute
Charlotte, North Carolina, United States
The Ohio State University
Columbus, Ohio, United States
Oregon Health Sciences University
Portland, Oregon, United States
Geisinger Health Systems
Danville, Pennsylvania, United States
Vanderbilt University Medical Center
Nashville, Tennessee, United States
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Dallas, Texas, United States
University of Utah, Huntsman Cancer Institute
Salt Lake City, Utah, United States
Fred Hutchinson Cancer Research Center
Seattle, Washington, United States
Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Related Links
Access external resources that provide additional context or updates about the study.
Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease (THRIVE)
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MA-GVHD-401
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.